PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced that as a result of recent discussions with the U.S. Food and Drug Administration (FDA), PURE intends to resubmit its Food Contact Notification for use of its SDC antimicrobial in raw poultry processing before the end of June.
SDC test results demonstrate materially significant reduction of Salmonella contamination in poultry. The data indicates that the use of an SDC antimicrobial solution in poultry processing has the potential to enable processing plants to achieve non-detectable Salmonella levels post-chill process.
Management intends to provide additional information about the re-submission, including a discussion of timing and the potential approval process, during its fiscal Q3 results conference call.
CEO Hank R. Lambert says, “The results of recent testing indicate a significant reduction of silver residues on poultry treated with SDC to nearly nondetectable levels. We believe this data adequately addresses the FDA’s prior issues. We look forward to the completion of the regulatory review process in order to bring SDC to market as an effective intervention component of an integrated food safety system for poultry processing.”